Registered user of Farmavita.Net is looking for EU CTD Dossier with supply for DOCETAXEL injection concentrate. Product is sought for non-EU markets, where data exclusivity and patents are not in force.
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel has an approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline-based chemotherapy and failed to stop cancer progression or relapsed. Administered as a one-hour infusion every three weeks generally over a ten cycle course, docetaxel is considered better than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule agent.
Offer is valid subject to confirmation of patent non infringement status of product. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights. Farmavita.Net is not owner of offered products/licenses and do not take any liability related to them. However, as the licensing agent we do our best to facilitate that closed licensing agreements are made on mutual benefit of contracting parties and without infringement of intellectual property of third parties.
|Pharma licensing||In-licensing (demand)|